Retension Pharmaceuticals, Inc. (NASDAQ: RTSN), a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular diseases, announced the pricing of its upsized initial public offering of 3,750,000 shares of common stock at $12 per share. The offering is expected to generate gross proceeds of $45 million before underwriting discounts, commissions, and other expenses. The company also granted underwriters a 30-day option to purchase up to an additional 562,500 shares to cover over-allotments, if any. Shares were expected to begin trading on the Nasdaq Capital Market on Oct. 9, 2026, and the offering is scheduled to close on or about Oct. 13, subject to customary closing conditions.
Retension intends to use the net proceeds, together with existing cash and cash equivalents, to complete its Phase 2b clinical trial of RTN-001 for uncontrolled hypertension and to prepare for, support, and advance a planned Phase 3 trial. Remaining funds will be allocated to general corporate purposes and operating expenses. RTN-001 is the company's lead clinical candidate, in development for patients with uncontrolled and resistant hypertension—conditions that affect millions worldwide and often lead to severe cardiovascular complications if not adequately managed. For more information, visit the company's website at https://www.retensionpharmaceuticals.com/.
The offering is being managed by a syndicate of investment banks, with Leerink Partners, Guggenheim Securities, and Oppenheimer & Co. serving as joint bookrunning managers, and Titan Partners acting as lead manager. The involvement of these reputable firms underscores institutional confidence in Retension's pipeline and strategic direction. For market data on Retension (NASDAQ: RTSN), visit Retension (NASDAQ: RTSN).
The successful upsized IPO provides Retension with critical capital to advance its clinical programs at a time when demand for innovative hypertension therapies remains high. Uncontrolled hypertension is a leading risk factor for heart disease, stroke, and kidney failure, and current treatment options often fail to achieve target blood pressure in a significant portion of patients. If RTN-001 proves effective in later-stage trials, it could offer a new mechanism of action for patients who do not respond adequately to existing therapies. This would not only benefit patients but also position Retension as a potential player in a multi-billion-dollar cardiovascular drug market.
InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication, distributed the announcement. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For full terms of use and disclaimers, see https://www.InvestorWire.com/Disclaimer. To view the full press release, visit https://ibn.fm/uko0m.
